AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene’s VAXINIA MAST trial has cleared intratumoral combination cohort 1.
- In the clinical trial, VAXINIA is being administered along with Pembrolizumab.
- The company has moved to recruitment for cohort 2 of the intratumoral and intravenous arm in the combination study.
Imugene Limited (ASX: IMU) has shared that its Phase 1 CF33-hNIS (VAXINIA) MAST (metastatic advanced solid tumours) trial has cleared cohort 1 of the intratumoral (IT) arm in the combination study. As a part of the study, VAXINIA is being administered along with Pembrolizumab.
With this development, IMU has advanced to recruitment for cohort 2 of the IT and intravenous arms in the combination study. Also, the recruitment has commenced for cohort 4 of each of the arms of the VAXINIA monotherapy dose escalation.
Data Source: Company update
Details of the clinical trial
In the clinical trial, a low dosage of VAXINIA was given to patients with advanced solid or metastatic tumours who had gone through a minimum of two previous lines of standard of care treatment.
The City of Hope has developed the oncolytic virus which has been demonstrated to shrink different type of tumours in animal models and preclinical laboratories.
The title of the clinical trial is –
Data Source: Company update
The trial intends to recruit a maximum of 100 patients across ~10 Australian and US trial sites. The study began in May last year and is expected to run for almost two years.
Funding of this trial is being covered through existing resources and budgets.
